The viral vector-based gene therapy market size has grown rapidly in recent years. It will grow from $6.77 billion in 2025 to $7.93 billion in 2026 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to advancements in molecular biology research, increasing understanding of genetic disorders, early clinical successes of viral vector therapies, expansion of orphan drug programs, availability of viral vector platforms.
The viral vector-based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $14.81 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to increasing approvals of gene therapy products, rising investment in rare disease treatments, expansion of precision medicine initiatives, growing adoption of personalized healthcare, continuous improvements in vector engineering technologies. Major trends in the forecast period include rising adoption of targeted gene therapies, growing development of personalized treatment approaches, expansion of clinical trials for rare diseases, increasing focus on long-term therapeutic efficacy, enhanced emphasis on vector safety and performance.
The rising prevalence of genetic diseases is expected to drive the growth of the viral vector‑based gene therapy market in the coming years. Genetic diseases are disorders caused by DNA mutations, which can be inherited or occur spontaneously, affecting health, development, or bodily functions. The increase in these diseases is linked to greater awareness and advances in diagnostic technologies, enabling earlier and more accurate identification of previously undiagnosed conditions. Viral vector‑based gene therapy supports the management of genetic diseases by delivering therapeutic genes directly to target cells, making it particularly effective for inherited disorders. It slows disease progression by providing precise and long-lasting correction of genetic defects, improving patient outcomes and quality of life. For example, in April 2025, the International Diabetes Federation (IDF), a Belgium-based non-profit organization, reported that around 589 million people were living with diabetes in 2024, with projections reaching 853 million by 2050. Therefore, the growing prevalence of genetic diseases is fueling the viral vector‑based gene therapy market.
Key players in the viral vector‑based gene therapy market are focusing on developing advanced platforms, such as integrated manufacturing systems, to increase efficiency, improve reliability, and reduce the cost and time of therapy production. Integrated manufacturing platforms are comprehensive systems that streamline the entire gene therapy production process - from vector design to final product - using standardized, high-yield workflows. For instance, in October 2024, Forge Biologics Holdings LLC, a US-based biotechnology company, launched the FUEL AAV Manufacturing Platform. This proprietary, suspension-based system is designed for high productivity and scalability. It features a fully integrated plasmid system and optimized processes, enabling robust and consistent production of adeno-associated viral (AAV) vectors for gene therapies, thereby accelerating timelines from research to clinical trials.
In July 2023, Sartorius AG, a Germany-based provider of laboratory and biopharmaceutical equipment and services, acquired Polyplus SAS for an undisclosed sum. Through this acquisition, Sartorius aims to enhance its capabilities in supplying critical transfection reagents and related technologies, facilitating efficient production of viral vectors for gene and gene-modified cell therapies. Polyplus SAS, based in France, provides upstream technologies, products, and services for the manufacturing of viral vectors used in gene therapies.
Major companies operating in the viral vector-based gene therapy market are F. Hoffmann-La Roche AG, Novartis AG, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Inc., Rocket Pharmaceuticals Inc., PTC Therapeutics Inc., 4D Molecular Therapeutics Inc., Editas Medicine Inc., Regenxbio Inc., Oxford Biomedica plc, MeiraGTx Holdings plc, Voyager Therapeutics Inc., Solid Biosciences Inc., Sangamo Therapeutics Inc., Adverum Biotechnologies Inc., Passage Bio Inc., Dyno Therapeutics Inc., uniQure N.V., Bluebird Bio Inc.
North America was the largest region in the viral vector-based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector-based gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the viral vector-based gene therapy market by increasing costs of imported viral vector components, manufacturing equipment, clinical trial supplies, and cold-chain logistics solutions. Pharmaceutical companies and research institutions in North America and Europe are most affected due to dependence on imported materials, while Asia-Pacific faces higher costs in scaling clinical manufacturing. These tariffs are increasing development costs and extending commercialization timelines. However, they are also supporting domestic manufacturing expansion, regional clinical trial infrastructure development, and increased investment in localized gene therapy production capabilities.
The viral vector-based gene therapy market research report is one of a series of new reports that provides viral vector-based gene therapy market statistics, including viral vector-based gene therapy industry global market size, regional shares, competitors with a viral vector-based gene therapy market share, detailed viral vector-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector-based gene therapy industry. This viral vector-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Viral vector-based gene therapy is a medical approach that uses engineered viruses to deliver therapeutic genes into a patient’s cells to treat or prevent diseases. The viral vectors are modified to be safe and replication-deficient while efficiently transferring genetic material to target cells. This therapy enables the correction of genetic defects, modulation of gene expression, or stimulation of immune responses to achieve long-lasting therapeutic effects.
The main vector types in viral vector-based gene therapy include adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, retroviral vectors, and others. Adenoviral vectors are engineered viruses derived from adenoviruses, modified to safely deliver therapeutic genes into target cells without replicating, and are commonly used in gene therapy and vaccine applications. Delivery routes include intravenous, intrathecal, intramuscular, subcutaneous, and topical administration. Applications span oncology, genetic disorders, cardiovascular diseases, infectious diseases, neurological disorders, and more, serving end users such as hospitals, clinical research organizations (CROs), academic and research institutes, and pharmaceutical and biotechnology companies.
The viral vector-based gene therapy market includes revenues earned by entities through process development, vector design, cell line development, assay development, process optimization, manufacturing, upstream production, and downstream purification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The viral vector-based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $14.81 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to increasing approvals of gene therapy products, rising investment in rare disease treatments, expansion of precision medicine initiatives, growing adoption of personalized healthcare, continuous improvements in vector engineering technologies. Major trends in the forecast period include rising adoption of targeted gene therapies, growing development of personalized treatment approaches, expansion of clinical trials for rare diseases, increasing focus on long-term therapeutic efficacy, enhanced emphasis on vector safety and performance.
The rising prevalence of genetic diseases is expected to drive the growth of the viral vector‑based gene therapy market in the coming years. Genetic diseases are disorders caused by DNA mutations, which can be inherited or occur spontaneously, affecting health, development, or bodily functions. The increase in these diseases is linked to greater awareness and advances in diagnostic technologies, enabling earlier and more accurate identification of previously undiagnosed conditions. Viral vector‑based gene therapy supports the management of genetic diseases by delivering therapeutic genes directly to target cells, making it particularly effective for inherited disorders. It slows disease progression by providing precise and long-lasting correction of genetic defects, improving patient outcomes and quality of life. For example, in April 2025, the International Diabetes Federation (IDF), a Belgium-based non-profit organization, reported that around 589 million people were living with diabetes in 2024, with projections reaching 853 million by 2050. Therefore, the growing prevalence of genetic diseases is fueling the viral vector‑based gene therapy market.
Key players in the viral vector‑based gene therapy market are focusing on developing advanced platforms, such as integrated manufacturing systems, to increase efficiency, improve reliability, and reduce the cost and time of therapy production. Integrated manufacturing platforms are comprehensive systems that streamline the entire gene therapy production process - from vector design to final product - using standardized, high-yield workflows. For instance, in October 2024, Forge Biologics Holdings LLC, a US-based biotechnology company, launched the FUEL AAV Manufacturing Platform. This proprietary, suspension-based system is designed for high productivity and scalability. It features a fully integrated plasmid system and optimized processes, enabling robust and consistent production of adeno-associated viral (AAV) vectors for gene therapies, thereby accelerating timelines from research to clinical trials.
In July 2023, Sartorius AG, a Germany-based provider of laboratory and biopharmaceutical equipment and services, acquired Polyplus SAS for an undisclosed sum. Through this acquisition, Sartorius aims to enhance its capabilities in supplying critical transfection reagents and related technologies, facilitating efficient production of viral vectors for gene and gene-modified cell therapies. Polyplus SAS, based in France, provides upstream technologies, products, and services for the manufacturing of viral vectors used in gene therapies.
Major companies operating in the viral vector-based gene therapy market are F. Hoffmann-La Roche AG, Novartis AG, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Inc., Rocket Pharmaceuticals Inc., PTC Therapeutics Inc., 4D Molecular Therapeutics Inc., Editas Medicine Inc., Regenxbio Inc., Oxford Biomedica plc, MeiraGTx Holdings plc, Voyager Therapeutics Inc., Solid Biosciences Inc., Sangamo Therapeutics Inc., Adverum Biotechnologies Inc., Passage Bio Inc., Dyno Therapeutics Inc., uniQure N.V., Bluebird Bio Inc.
North America was the largest region in the viral vector-based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector-based gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the viral vector-based gene therapy market by increasing costs of imported viral vector components, manufacturing equipment, clinical trial supplies, and cold-chain logistics solutions. Pharmaceutical companies and research institutions in North America and Europe are most affected due to dependence on imported materials, while Asia-Pacific faces higher costs in scaling clinical manufacturing. These tariffs are increasing development costs and extending commercialization timelines. However, they are also supporting domestic manufacturing expansion, regional clinical trial infrastructure development, and increased investment in localized gene therapy production capabilities.
The viral vector-based gene therapy market research report is one of a series of new reports that provides viral vector-based gene therapy market statistics, including viral vector-based gene therapy industry global market size, regional shares, competitors with a viral vector-based gene therapy market share, detailed viral vector-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector-based gene therapy industry. This viral vector-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Viral vector-based gene therapy is a medical approach that uses engineered viruses to deliver therapeutic genes into a patient’s cells to treat or prevent diseases. The viral vectors are modified to be safe and replication-deficient while efficiently transferring genetic material to target cells. This therapy enables the correction of genetic defects, modulation of gene expression, or stimulation of immune responses to achieve long-lasting therapeutic effects.
The main vector types in viral vector-based gene therapy include adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, retroviral vectors, and others. Adenoviral vectors are engineered viruses derived from adenoviruses, modified to safely deliver therapeutic genes into target cells without replicating, and are commonly used in gene therapy and vaccine applications. Delivery routes include intravenous, intrathecal, intramuscular, subcutaneous, and topical administration. Applications span oncology, genetic disorders, cardiovascular diseases, infectious diseases, neurological disorders, and more, serving end users such as hospitals, clinical research organizations (CROs), academic and research institutes, and pharmaceutical and biotechnology companies.
The viral vector-based gene therapy market includes revenues earned by entities through process development, vector design, cell line development, assay development, process optimization, manufacturing, upstream production, and downstream purification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Viral Vector-Based Gene Therapy Market Characteristics
3. Viral Vector-Based Gene Therapy Market Supply Chain Analysis
4. Global Viral Vector-Based Gene Therapy Market Trends and Strategies
5. Viral Vector-Based Gene Therapy Market Analysis of End Use Industries
7. Global Viral Vector-Based Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Viral Vector-Based Gene Therapy Total Addressable Market (TAM) Analysis for the Market
9. Viral Vector-Based Gene Therapy Market Segmentation
10. Viral Vector-Based Gene Therapy Market Regional and Country Analysis
11. Asia-Pacific Viral Vector-Based Gene Therapy Market
12. China Viral Vector-Based Gene Therapy Market
13. India Viral Vector-Based Gene Therapy Market
14. Japan Viral Vector-Based Gene Therapy Market
15. Australia Viral Vector-Based Gene Therapy Market
16. Indonesia Viral Vector-Based Gene Therapy Market
17. South Korea Viral Vector-Based Gene Therapy Market
18. Taiwan Viral Vector-Based Gene Therapy Market
19. South East Asia Viral Vector-Based Gene Therapy Market
20. Western Europe Viral Vector-Based Gene Therapy Market
21. UK Viral Vector-Based Gene Therapy Market
22. Germany Viral Vector-Based Gene Therapy Market
23. France Viral Vector-Based Gene Therapy Market
24. Italy Viral Vector-Based Gene Therapy Market
25. Spain Viral Vector-Based Gene Therapy Market
26. Eastern Europe Viral Vector-Based Gene Therapy Market
27. Russia Viral Vector-Based Gene Therapy Market
28. North America Viral Vector-Based Gene Therapy Market
29. USA Viral Vector-Based Gene Therapy Market
30. Canada Viral Vector-Based Gene Therapy Market
31. South America Viral Vector-Based Gene Therapy Market
32. Brazil Viral Vector-Based Gene Therapy Market
33. Middle East Viral Vector-Based Gene Therapy Market
34. Africa Viral Vector-Based Gene Therapy Market
36. Viral Vector-Based Gene Therapy Market Competitive Landscape and Company Profiles
37. Viral Vector-Based Gene Therapy Market Other Major and Innovative Companies
40. Viral Vector-Based Gene Therapy Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Viral Vector-Based Gene Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses viral vector-based gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for viral vector-based gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The viral vector-based gene therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Vector Type: Adenoviral Vectors; Adeno-Associated Viral Vectors; Lentiviral Vectors; Retroviral Vectors2) By Delivery Method: Intravenous Injection; Intrathecal Injection; Intramuscular Injection; Subcutaneous Injection; Topical
3) By Application: Oncology; Genetic Disorders; Cardiovascular Diseases; Infectious Diseases; Neurological Disorders; Other Applications
4) By End-User: Hospitals; Clinical Research Organizations (CROs); Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Adenoviral Vectors: Human Adenovirus Serotype Five; Human Adenovirus Serotype Two; Canine Adenovirus2) By Adeno-Associated Viral Vectors: Adeno-Associated Virus Serotype One; Adeno-Associated Virus Serotype Two; Adeno-Associated Virus Serotype Five; Adeno-Associated Virus Serotype Eight; Other Adeno-Associated Viruses
3) By Lentiviral Vectors: Human Immunodeficiency Virus One; Human Immunodeficiency Virus Two
4) By Retroviral Vectors: Gammaretrovirus; Alpharetrovirus; Spumaretrovirus; Other Retroviruses
Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; BioMarin Pharmaceutical Inc.; Sarepta Therapeutics Inc.; Ultragenyx Inc.; Rocket Pharmaceuticals Inc.; PTC Therapeutics Inc.; 4D Molecular Therapeutics Inc.; Editas Medicine Inc.; Regenxbio Inc.; Oxford Biomedica plc; MeiraGTx Holdings plc; Voyager Therapeutics Inc.; Solid Biosciences Inc.; Sangamo Therapeutics Inc.; Adverum Biotechnologies Inc.; Passage Bio Inc.; Dyno Therapeutics Inc.; uniQure N.V.; Bluebird Bio Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Viral Vector-Based Gene Therapy market report include:- F. Hoffmann-La Roche AG
- Novartis AG
- BioMarin Pharmaceutical Inc.
- Sarepta Therapeutics Inc.
- Ultragenyx Inc.
- Rocket Pharmaceuticals Inc.
- PTC Therapeutics Inc.
- 4D Molecular Therapeutics Inc.
- Editas Medicine Inc.
- Regenxbio Inc.
- Oxford Biomedica plc
- MeiraGTx Holdings plc
- Voyager Therapeutics Inc.
- Solid Biosciences Inc.
- Sangamo Therapeutics Inc.
- Adverum Biotechnologies Inc.
- Passage Bio Inc.
- Dyno Therapeutics Inc.
- uniQure N.V.
- Bluebird Bio Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.93 Billion |
| Forecasted Market Value ( USD | $ 14.81 Billion |
| Compound Annual Growth Rate | 16.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
